1. Introduction {#s0005}
===============

Cancer is a group of diseases characterized by the abnormal growth and proliferation of cells that may or may not invade or spread to other parts of the body. According to data from World Health Organization, cancer is the second cause of death worldwide and caused more than 8.8 million deaths in 2015 ([@b0315]).

The high rates of cancer incidence have encouraged the interest of researchers in the developing of new therapeutic modalities against it, and in the finding of new drugs with better activity and lower adverse effects. In this scenario, natural products have been considered useful to the anticancer activity. It is known that approximately 55% of the anticancer drugs approved between 1940 and 2014 had their origin from natural sources ([@b0185]).

Several studies suggest that metabolites derived from plants may have pro-apoptotic properties. *Viscum album* L. (Santalaceae), commonly known as mistletoe, is a semi-parasitic plant that grows on different host trees. This species has been commonly used for complementary cancer therapy, mainly in Central Europe ([@b0270]), and it is possible to find a multitude of studies in which the immunomodulatory ([@b0115], [@b0075]; [@b0305]), cytotoxic and pro-apoptotic ([@b0040], [@b0280], [@b0065]) properties have been described. Aqueous preparations of *V. album* exert several immuno-stimulatory mechanisms, possibly by interacting with the cellular and humoral compartments of the immune system, increasing the antitumor immune response ([@b0325], [@b0245], [@b0090], [@b0075]).

The most studied active compounds in aqueous preparations of *V. album* are lectins and viscotoxins. These compounds induce macrophage cytotoxicity, stimulate phagocytosis of immune cells, increase cytokine secretion and enhance *in vitro* cytotoxic effects on various cell lines ([@b0265], [@b0060]).

Other compounds, such as phenolic acids, phenylpropanoids, flavonoids, triterpenes, phytosterols, oligo and polysaccharides, were also identified in the European mistletoe ([@b0180], [@b0050], [@b0250]; [@b0045]) and this variety of metabolites is probably involved with the antitumoral effects of *V. album* extracts.

Although *V. album* antitumor activity is mainly associated with the aqueous preparations, the use of different solvents as well as modifications in the extraction methodology influences *in vitro* and *in vivo* antitumor activity. It must be taken into account that the chemical composition of *V. album* extracts is directly related to the solvent used in the extraction process.

In this context, the cytotoxicity of *V. album* hydroalcoholic tincture associated or not with chemotherapeutic agents was detected in the Ehrlich ascites carcinoma ([@b0240]), as well as in HeLa cancer cells proliferation ([@b0220]), indicating that ethanol soluble compounds are also related to the antitumoral *V. album* activity. Moreover, [@b0045] showed the efficacy of non-polar supercritical CO~2~ extract in the cytotoxicity of *V. album* towards Ehrlich carcinoma cells, confirming the importance of the optimization extraction methodology.

The purpose of the present study was to analyze the chemical profile of two *V. album* tinctures, as well as their *in vitro* effects in tumoral (murine melanoma cells, B16F10; human chronic myelogenic leukemia cell line, K562) and non-tumoral cells (monkey kidney cells, MA-104). The involvement of the identified chemical compounds with antitumoral *V. album* activity is also discussed in this paper.

2. Material and methods {#s0010}
=======================

*2.1*. *Viscum album* L. Tinctures {#s0015}
----------------------------------

Tinctures of *Viscum album* L. used in this study were donated by two pharmaceutical laboratories, Homeopatia Almeida Prado (São Paulo, Brazil) and Boiron Laboratories (Lyon, France), for research purposes. Both tinctures were obtained by maceration extraction with ethanol (45% v/v) following *Viscum album* homeopathic monographs in pharmacopoeias ([@b0010], [@b0020]) and were labeled Tinctures TA and TB.

2.2. Identification of substances by thin layer chromatography {#s0020}
--------------------------------------------------------------

Thin layer chromatography (TLC) analyses were achieved by silica gel 60 F254 (250 µm thickness, SiliCycle, Quebec, Canada) using water/methanol/glacial acetic acid/methylene chloride (2:3:8:15) as mobile phases. The detections were done by spraying NP/PEG reagent (1% diphenylboriloxyethylamine in methanol p/v, followed by 5% polyethylene glycol 4000 in ethanol p/v). The plates were observed under ultraviolet light at 254 and 365 nm before and after spraying the reagent solution. Spots of non-diluted tinctures and standards were identified by Rf-values and color compared to the standard compounds caffeic and chlorogenic acids ([@b0010]) (MP Biomedicals, California, USA).

2.3. HPLC-PDA-MS conditions {#s0025}
---------------------------

Analyses were conducted using an HPLC Dionex Ultimate 3000, equipped with a photodiode array (PAD) detector (Thermo Fisher Scientific, USA) connected with LCQ Fleet Ion Trap Mass Spectrometer (Thermo Fisher Scientific, USA). The sample was prepared according to *V. album* monograph from French Pharmacopoeia ([@b0010]): in a 20.0 mL volumetric flask, 8.0 g of each tincture was diluted to 20.0 mL of a mixture of 10 volumes of acetonitrile and 90 volumes of trifluoroacetic acid (0.05 per cent v/v).

Separations were performed on a reverse-phase column (C-18, 250 mm × 4, 6 mm × 5.0 μm; Kromasil, Akzo Nobel). Water-formic acid 0.1% v/v (A) and acetonitrile (B) were used as mobile phases, as follows: (i) 0--20 min, 10% B, (ii) 20--25 min, 10--15% B, (iii) 25--45 min, 15% B, (iv) 45--50 min, 15--100% B, (v) 50--55 min 100% B, (vi) 55--57 min 100--10%, and (vii) 57--70 min 10% B. The flow rate was 1.0 mL/min and the injection volume was 20 µL. Absorption UV--VIS spectra were recorded on PDA-detector (with a total spectral range between 100 nm and 400 nm), set at detection wavelength 220 nm, simultaneously. Mass spectra were recorded in positive ion mode.

2.4. UFLC-PDA-MS/MS conditions {#s0030}
------------------------------

UFLC‑PDA‑MS/MS analyses were carried out on an ultra fast liquid chromatography (UFLC Shimadzu, model Nexera) equipped with a mass spectrometer (TOF Bruker, model Compact). The sample was prepared according to *V. album* monograph from French Pharmacopoeia ([@b0010]) as described in Section [2.3](#s0025){ref-type="sec"}.

Separations were performed on a reverse-phase column (C-18, 100 mm × 3 mm × 2.6 μm; Kinetex, Phenomenex). A binary gradient system with water-formic acid 0.1% v/v (A) and acetonitrile (B) was used as follows: (i) 0--7.65 min, 5% B, (ii) 7.65--8.50 min, 5--15% B, (iii) 8.50--15.30 min, 15% B, (iv) 15.30--17 min, 15--100% B, (v) 17--18.70 100% B, (vi) 18.70--20.40 min 100--5% and (vii) 20.40--22 min 5% B. The flow rate was 0.5 mL/min and the injection volume was 2 µL. The detection wavelength was 220 nm. All analyses were done by electrospray ionization (ESI) in positive mode.

2.5. UHPLC-HRMS/MS conditions {#s0035}
-----------------------------

Samples were prepared as described in Section [2.3](#s0025){ref-type="sec"} ([@b0010]) and analyzed on Dionex Ultimate 3000 system hyphenated to a QExactive Plus mass spectrometer (Thermo Fisher Scientific, USA) equipped with an electrospray ionization (ESI) probe. Separations were performed on a reverse-phase (C-18, 50 mm, 2, 1 mm × 1.7 μm; Syncronis, Thermo Fisher Scientific). Water-formic acid 0.1% v/v (A) and acetonitrile (B) were used as mobile phases as follows: (i) 0--2 min, 10% B, (ii) 2--3,5 min, 10--15% B, (iii) 3.5--6.4 min, 15% B, (iv) 6.4--7.0 min, 15--100% B, (v) 7.0--8.0 min 100% B, (vi) 8.0--9.2 min 100--10% and (vii) 9.2--10 min 10% B. The flow rate was 1.0 mL/min and the injection volume was 5 µL. Mass spectra were recorded in negative ion mode. The HRMS and HRMS/MS data were acquired in negative mode over a *m*/*z* range of 80--1000. The MS profile was performed in full scan mode and displayed in TIC (Total Ion Current) chromatogram. ESI conditions were as follows: capillary temperature 380 °C; spray voltage 3.9 kV; ESI voltage 2.9 kV. Nitrogen was used as sheath gas (60 Au) and auxiliary gas (20 Au). The raw data were acquired and processed with Xcalibur 2.0.7 software from Thermo Scientific.

2.6. Cell lines and culture {#s0040}
---------------------------

B16F10 cells (murine melanoma) was obtained from Laboratório de Oncobiologia Molecular (LabOMol), Federal University of Rio de Janeiro, the K562 (human chronic myelogenic leukemia cell line) and MA-104 (monkey kidney, non-tumoral) were obtained from Rio de Janeiro Cell Bank (Duque de Caxias, Rio de Janeiro, Brazil). Cells were grown in Dulbecco's Modified Eagle Medium (DMEM) in 25 cm^2^ disposable plastic bottles (TPP Techno Plastic Products AG, Switzerland), at 37 °C. They were supplemented with 10% fetal bovine serum, penicillin (100 UI/mL) and streptomycin (100 µg/mL). These supplements were obtained from Invitrogen (California, USA),

2.7. Cell viability assay {#s0045}
-------------------------

Cell viability was measured by MTT colorimetric assay as described before ([@b0175], [@b0165]). Briefly, for each experiment, 1 × 10^4^ cells were seeded per well in 96-well plates. After 24 h, cells were treated with TA and TB in concentrations varying from 1 to 5% v/v. After incubation for 24 h, the cells were centrifuged for 8 min (500*g*) and the supernatant was discarded. In each well, 180 µL of DMEM and 20 µL of a 5 mg/mL solution of Thiazolyl Blue Tetrazolium Bromide (MTT - Sigma, USA) were added, and cells were incubated for further 3 h at 37 °C. After incubation, cells were centrifuged, the supernatant was discarded and 200 µL of Dimethyl Sulfoxide (DMSO) were added per well to dissolve the newly formed formazan salt. The absorbance was measured at 490 nm using an ELISA plate reader (TP Reader, Thermoplate). Mean values were calculated in 3 independent experiments using 5 wells per condition.

2.8. May-Grunwald-Giemsa assay {#s0050}
------------------------------

B16F10 cells (5 × 10^5^ cells/ well) were cultivated in 6-well plate and incubated with TA, TB and their respective controls, at the concentrations of 3% and 5% v/v for 24 h. Subsequently, cells were washed and stained with May-Grunwald-Giemsa, as described before ([@b0165], [@b0025]). Finally, morphological alterations were examined with a light microscopy (Axioplan 2, Carl Zeiss, Göttingen, Germany), and all images were obtained using a digital camera attached to the microscope.

2.9. DNA fragmentation analysis {#s0055}
-------------------------------

DNA fragmentation was performed as follows: B16F10 cells were seeded to approximately 80% of confluence (3.5 × 10^5^ cells) in 25 cm^2^ disposable plastic bottles and incubated for 24 h, at 37 °C. Cells were treated with TA, TB and their respective hydro-alcoholic controls, in the concentrations of 3% and 5% v/v, and then incubated for more 6 h or 24 h at 37 °C. After that, cells were trypsinized, counted and diluted to obtain 1 × 10^6^ cells. Following, they were washed twice with PBS, and DNA extraction was performed according to the instructions from Wizard Genomic DNA Purification Kit (Promega, São Paulo, Brazil). For DNA ladder detection, the DNA samples extracted and the 1Kb DNA Ladder Marker (M1181, Sinapse, São Paulo, Brazil) were submitted to electrophoresis in 0.8% agarose gel. After 30 min, the gel was labeled with ethidium bromide, visualized in UV and photographed (Red®, Protein Simple, California, USA).

2.10. Apoptosis measurement {#s0060}
---------------------------

Apoptosis induction was measured as follows: B16F10 cells were seeded on 6-well plates at a concentration of 1 × 10^5^ cell/well. After 24 h, cells were treated with TB, TA and their respective controls in the concentrations of 3% and 5% v/v. After incubation for 6 h, the supernatants were collected, cells were trypsinized and added to the supernatants. Then, the suspensions were centrifuged and washed with cold PBS. The pellets were resuspended in 100 μL of FITC Annexin V Apoptosis Detection Kit I buffer (BD Biosciences, Pharmingen^TM^), homogenized and transferred to flow cytometry tubes. Cells were then stained with annexin V-FITC and propidium iodide (PI) according to the manufacturer instructions for 15 min at room temperature, in the dark. After this time, cells were analyzed in FACSVerse (Beckton and Dickinson, USA). The percentages of apoptotic cells were evaluated using BD FACSuite software.

2.11. Cell cycle analysis {#s0065}
-------------------------

Cell cycle was evaluated by flow cytometry as follows: 24 h after cell incubation with 3% or 5% v/v TA or TB and their respective controls, cells were trypsinized, centrifuged and washed with PBS. The tubes were then centrifuged for 10 min (450*g*), the supernatant was discarded and the pellet was resuspended in 500 μL of propidium iodide solution (40 µg/mL) in the presence of 100 µg/ml RNase in PBS. The solution was homogenized and transferred to flow cytometry tubes. After incubation for 30 min at room temperature in the dark, the cell cycle was analyzed with a FACSVerse flow cytometer (Beckton and Dickinson, USA). The percentages of cells in the cell cycle phases G0/G1, S, G2/M and sub G0 were determined using BD FACSuite software.

2.12. Statistical analysis {#s0070}
--------------------------

All experiments were performed at least three different times, and results were analyzed by ANOVA (analysis of variance) with Dunnett post hoc test, using GraphPad 5 Software (California, USA). *P* values\<.05 were considered statistically significant.

3. Results {#s0075}
==========

3.1. Chemical profile of *Viscum album* tinctures {#s0080}
-------------------------------------------------

TLC plate of TA and TB showed blue zones, which are typical of phenolic acids at 365 nm UV light, after it was sprayed with NP/PEG reagent ([@b0300]). TLC plate of TA sample showed one spot with Rf value (0.66) and similar color (fluorescent blue) to the chlorogenic acid reference compound. TB chromatoplate exhibited two fluorescent blue spots, one with Rf value equal to caffeic acid (Rf of 0.91) and another similar to the chlorogenic acid standard (Rf of 0.66).

UFLC-PDA-MS/MS analysis of TA tincture revealed phenolic acids and flavonoids with typical UV absorption spectrum and mass fragmentation pattern as major metabolites. In addition, these results support the previous phenolic acid and flavonoids identification by TLC plate, which showed fluorescent blue spots, typical of phenolic acid, and yellow spots, characteristic of flavonoids. UFLC chromatogram of TA, detected at 220 nm, showed three main peaks (**1**, **2** and **3**), whose MS and MS/MS spectra were carefully analyzed and compared with literature data. Compound **1** presented a typical UV absorption spectrum for phenolic acids ([@b0160]) and protonated molecular ion at *m*/*z* 355.1036 \[M+H\]^+^, with a mass fragmentation pattern similar to chlorogenic acid ([@b0210]). Compounds **2** and **3** showed an UV spectra with absorption spectrum corresponding to a flavonoid ([@b0160]) and protonated molecular ions at *m*/*z* 287.0925 \[M+H\]^+^ (C~16~H~14~O~5~) and 287.0924 \[M+H\]^+^ (C~16~H~14~O~5~) ([@b0285], [@b0180]). According to the MS/MS spectra of **2** and **3**, *m*/*z* 285.0767, 242.0580, 167.0344, 147.0446, 119.0497 and 91.0548 \[M+H\]^+^ ions had a typical ion fragmentation for sakuranetin and naringenin 5-methyl ether, when compared with previously reported data ([@b0080], [@b0215]).

TB tincture was analyzed initially by HPLC-PDA-MS, and the chromatogram at 220 nm exhibited six main peaks (**4**, **5**, **6**, **7**, **8** and **9**), as shown in [Fig. 1](#f0005){ref-type="fig"}. The UV spectra of those peaks showed absorption similar to phenolic acids and lignans ([@b0160]; [@b0030]). Mass analysis of each peak exhibited the following protonated molecular ions at *m*/*z*: 354.91 \[M+H\]^+^, 395.18 \[M+Na\]^+^, 527.24 \[M+Na\]^+^, 203.95 \[M+Na\]^+^, 599.87 \[M+NH~4~\]^+^ and 599.88 \[M+NH~4~\]^+^, respectively. In addition, mass spectral fragmentation pattern and UV spectrum of compounds **4**--**9** were compared to literature data, especially to those phenolic acids and lignans described as chemical markers of *V. album* ([@b0285]). Afterwards, the identification of compounds 4--9 was followed by accurate mass measurements through UHPLC-HRMS/MS analysis that presented deprotonated molecular ion peaks for compounds **4**, **5**, **6**, **7**, **8** and **9** at *m*/*z*: 353.08844 \[M−H\]^−^ (C~16~H~18~O~9~), 371.13513 \[M−H\]^−^ (C~17~H~24~O~9~), 503.17807 \[M−H\]^−^ (C~22~H~32~O~13~), 179.03498 \[M−H\]^−^ (C~9~H~8~O~4~), 581.22498\[M−H\]^−^ (C~28~H~38~O~13~) and 581.22527 \[M−H\]^−^ (C~28~H~38~O~13~), respectively.Fig. 1UV Chromatogram at 220 nm of TB sample.

MS/MS spectra of compound **4**, *m*/*z* 191.05521, 179.03458 and 135.04408 \[M−H\]^−^ ions, had a typical ion fragmentation for chlorogenic acid, according to the literature ([@b0340]). For some of the constituents, such as syringenin 4-*O*-glucoside (**5**) and syringenin 4-*O*-apiosyl-glucoside (**6)** fragment ions, it was observed that *m*/*z* 209, 194 and 175 is a syringenin fragmentation characteristic ([@b0255]). Compound **7** showed MS/MS spectra with ions at *m*/*z* 161 and 135 \[M−H\]^−^, similar to ion fragments of caffeic acid ([@b0340]).

In accordance with the accurate mass spectra of **8** and **9**, *m*/*z* 581.22498 \[M−H\]^−^ and 581.22527 \[M−H\]^−^ were typical for alangilignoside C and ligalbumoside A, as already described for *V. album* ([@b0190]; [@b0030]).

These results provided reliable information for confirming molecular weight and structure of these constituents. Therefore, compounds were identified as chlorogenic acid (**4**) ([@b0070], [@b0170]), syringenin 4-*O*-glucoside ([@b0195]) (eleutheroside B) (**5**), syringenin 4-*O*-apiosyl-glucoside (Panossian at al., 1998) (polygalatenoside E) (**6**), caffeic acid ([@b0235]) (**7**), alangilignoside C (**8**) and ligalbumoside A ([@b0190]; [@b0030]) (**9**). Compounds identified in *V. album* tinctures are shown in the [Fig. 2](#f0010){ref-type="fig"}.Fig. 2Possible structures present in TA and TB samples.

3.2. Cell viability is reduced by *Viscum album* L. {#s0085}
---------------------------------------------------

As shown in [Fig. 3](#f0015){ref-type="fig"}, control hydroalcoholic solutions decreased the viability of B16F10 and K562 cells in a dose-response way, having B16F10 presented a higher sensitivity. In contrast, MA-104 cell line was resistant to all hydroalcoholic concentrations used. Since the tumor cell lines were sensitive to the hydroalcoholic solutions, the same concentrations of these solutions were used as controls in the following experiments.Fig. 3MTT assay after 24 h of treatment with 45% v/v hydro-alcoholic solution. The final concentrations varied between 1 and 5% v/v. (A) MA-104, (B) K562, (C) B16F10. Data are shown as media ± SD from at least 3 experiments. ^\*^p \< .05, ^\*\*^p \< .001 and ^\*\*\*^p \< .0001, obtained with one way ANOVA with Dunnett post-test.

Both TA and TB were cytotoxic to the three cell lines, but this cytotoxicity was cell- and dose-dependent ([Fig. 4](#f0020){ref-type="fig"}). The MA-104 cell line was more sensitive to TA, which significantly diminished its viability in 50% (*p* \< .001) in concentrations as low as 1% v/v, while TB reduced viable cells in 24% when compared to control ([Fig. 4](#f0020){ref-type="fig"}, panel A). However, for the concentration of 5% v/v, TA and TB were equally effective, reducing MA-104 cell viability in approximately 36%. For K562 cells ([Fig. 4](#f0020){ref-type="fig"}, panel B) and B16F10 cells, both TA and TB were almost equally efficient in reducing the cellular viability at any concentration tested. At 5% v/v, TA and TB reduced K562 and B16F10 viability in approximately 70% ([Fig. 4](#f0020){ref-type="fig"}, panels B and C). Since B16F10 cell line has a well-known high aggressive and drug-resistant phenotype and presented similar results to K562 with both tinctures treatments, the following experiments were performed only with B16F10.Fig. 4MTT assay in MA-104 (panel A), K562 (panel B) and B16F10 (panel C) cells after 24 h of treatment with TA and TB solutions. The final concentrations varied between 1 and 5% v/v. Data are shown as media ± SD from at least 3 experiments. ^\*^p \< .05, ^\*\*^p \< .001 and ^\*\*\*^p \< .0001, obtained with one way ANOVA with Dunnett post-test.

3.3. Morphologic B16F10 alterations induced by TA and TB {#s0090}
--------------------------------------------------------

[Fig. 5](#f0025){ref-type="fig"} shows the morphology of B16F10 stained with Giemsa after 24 h of treatment, with TA and TB at concentrations of 3% and 5% v/v. Blebs, which were absent in the hydro-alcoholic control cells, can be seen in the plasma membrane ([Fig. 5](#f0025){ref-type="fig"} d, e, g - black arrows), suggesting apoptosis. Moreover, cells treated with 3% v/v also showed fusiform pattern cells.Fig. 5Representative photography of B16F10 Giemsa staining after 24 h of treatment. Cells were treated as stated in Section [2.8](#s0050){ref-type="sec"}. (a) Control, non-treated cells. (b) Cells treated with 3% v/v hydro-alcoholic solution. (c) Cells treated with 5% v/v hydro-alcoholic solution. (d) Cells treated with TA 3% v/v. (e) Cells treated with TA 5% v/v. (f) Cells treated with TB 3% v/v. (g) Cells treated with TB 5% v/v. The black arrows indicate possible blebs in the plasma membrane.

*3.4*. *Viscum album* tinctures induced DNA fragmentation in B16F10 cells {#s0095}
-------------------------------------------------------------------------

[Fig. 6](#f0030){ref-type="fig"} shows B16F10 genomic DNA fragmentation induced by TA and TB. A DNA degradation pattern can be observed in lanes 2, 3 and 6, corresponding respectively to TB and TA at 5% v/v (6h), and TB at 3% v/v (24 h). Finally, the absence of DNA fragmentation was detected when hydro-alcoholic solvents (3% and 5% v/v) were incubated with B16F10 for 24 h (lane 1) and for 6 h (lane 4).Fig. 6Genomic DNA fragmentation of B16F10 cells by *Viscum album* tinctures. Lane M: DNA ladder marker; Lane 1: hydro-alcoholic solution 5% v/v 6 h; Lane 2: TB 5% v/v 6 h; Lane 3: TA 5% v/v 6 h; Lane 4: hydro-alcoholic solution 3% v/v 24 h; lane 5: TA 3% v/v 24 h; lane 6: TB 3% v/v 24 h. The figure is representative of 3 (three) independent experiments.

3.5. Apoptosis evaluation by Annexin-V/FITC/PI {#s0100}
----------------------------------------------

Since the results above suggested that *V. album* tinctures induce apoptosis in B16F10, Annexin V-FITC/PI V-PI methodology was also employed to confirm this data. As it can be seen in [Fig. 8](#f0040){ref-type="fig"}-panel A, the number of viable cells was reduced by 22.5%, in relation to its respective control, after treatment with 3% v/v of TB. This reduction was accompanied by a 21% increase in the number of early apoptotic cells (PI-/Annexin+) ([Fig. 8](#f0040){ref-type="fig"}, panel B, left). On the other hand, no statistically significant differences (*p* \< .05), in relation to control, were detected after TA incubation.Fig. 8Apoptosis induced by treatment with TA and TB (3% and 5% v/v) for 6 h. Panel A -- cells not labeled with Annexin V-FITC or PI (viable cells). Panel B -- cells labeled with Annexin-V/FITC (early apoptosis). Panel C -- cells labeled with both Annexin-V/FITC and PI (late apoptosis). Panel D -- cells labeled only with PI (necrotic cells). Data are Mean ± SD of at least three independent experiments. ^\*^p \< .05; ^\*\*^p \< .001 and ^\*\*\*^p \< .0001, as obtained by one way ANOVA with Dunnet post-test.

Additionally, using higher tincture concentrations (5% v/v), statistically significant decreases in B16F10 viability were detected by 32% (TA) and 55% (TB), with *p* \< .0001 ([Fig. 8](#f0040){ref-type="fig"}, panel A, right). Nevertheless, [Fig. 8](#f0040){ref-type="fig"} (panel C, right) showed an increase of 18% (TA, *p* \< .05) and 41% (TB, *p* \< .0001) in late apoptotic cells (PI+/Annexin+). Finally, TA and TB led to an increase in PI labeled cells with percentages of 16.5% and 13.5% (*p* \< 0.05), respectively, suggesting necrosis or other non-apoptotic cell death pathways ([Fig. 8](#f0040){ref-type="fig"}, panel D, right).

*3.6*. *Viscum album* tinctures modified B16F10 cell cycle {#s0105}
----------------------------------------------------------

B16F10 cell cycles were evaluated after 24 h of treatment with TA and TB at 3% and 5% v/v. It can be seen in [Fig. 7](#f0035){ref-type="fig"} that SubG0 had an increase of 43% after 24 h of incubation with TB (3% v/v), and 80% after 24 h of incubation with both tinctures at 5% v/v. The percentage of cells in G0/G1 was reduced by 22% (TA) and 36% (TB) at 3% v/v, while TA treatment (3% v/v) induced an increase in the number of cells of 13% and 8% in S and G2/M phases, respectively.Fig. 7Effect of *Viscum album* tinctures on B16F10 cell cycle. Cells were treated with TA or TB at concentrations of 3% v/v (Panel A) or 5% v/v (panel B) for 24 h. Cells were incubated with PI and the DNA content was evaluated by flow cytometry, as described in Section [2.11](#s0065){ref-type="sec"}. Data represent the mean ± SD of at least three independent experiments. ^\*^p \< .05; ^\*\*^p \< .001 and ^\*\*\*^p \< .0001, as measured be one-way ANOVA with Dunnet post-test.

4. Discussion {#s0110}
=============

Cancer is one of the main causes of death worldwide. Natural products and their secondary metabolites have a considerable importance as anticancer agents considering their major toxicity to cancer cells when compared with normal cells ([@b0095]).

Several studies have reported cytotoxic activity of *V. album* aqueous extracts in different cell lines, such as MOLT-4 and Yoshida ([@b0275]), cells of tongue squamous cell carcinoma ([@b0140]), lymphoma human cells ([@b0225]), human T cell lines CEM and monocyte cell lines HL-60 ([@b0230]). The most important compounds involved with the antitumoral activity of *V. album* aqueous extracts are mistletoe lectins (I-III) ([@b0290]), viscotoxins and polysaccharides ([@b0275], [@b0270]). However, its antitumoral potential is controversial because there are studies confirming that non-aqueous extracts contain compounds, such as epi-oleanolic acid ([@b0110]), viscothionin ([@b0130]), and alkaloids ([@b0125]), which are also directly involved with antioxidative ([@b0135]) and, consequently, anti-tumoral properties. Recently, [@b0220]) showed that *V. album* alcoholic extract reduces Hela cells proliferation with no significant effects on normal fibroblasts, confirming the involvement of other bioactive molecules.

In the present study, we observed that hydroalcoholic *V. album* tinctures (TA and TB) were cytotoxic to tumoral cell lines (K562 and B16F10). Since mistletoe lectins are not stable in hydroalcoholic solvents, the anticancer activity of these extracts should be also attributed to the presence of different compounds from the ones in aqueous *V. album* preparations. Our results showed the presence of phenolic compounds in both TA and TB tinctures, confirming previous analyses done by other authors ([@b0205], [@b0145]).

According to the literature, caffeic and chlorogenic acids presented inhibitory activities against tumoral cells, evidencing the effects in the adhesion, proliferation, migration, and invasion of tumoral cells ([@b0320], [@b0310]). Caffeic acid phenethyl ester showed a decrease of melanoma cell migration due to a nuclear factor kappa B inhibition (NF-κB) ([@b0105]). Chlorogenic acid did not have cytotoxic effects on cellular viability when Hep3B cells were treated with different concentrations of this compound ([@b0100]). However, the same study demonstrated that chlorogenic acid inhibited the activity of the metalloproteinase-9 (MMP-9), related with tumor progression.

Flavanone sakuranetin present in TA is well-known in *V. album* ([@b0285]). However, the flavanone naringenin 5-methyl ether was described for the first time in this work. [@b0055] demonstrated by MTT assay the cytotoxic effects of sakuranetin (0--75 μmol/L) in B16BL6 melanoma cells after 72 h of treatment.

Phenylpropanoids and lignan are other classes of secondary metabolites with important anticancer activity. Etoposide and teniposide, two important anticancer drugs, were derived from lignan podophyllotoxin presented in genus *Podophyllum* ([@b0035]). In the present work, two phenylpropanoids and two lignans were identified in TB sample, syringenin 4-*O*-glucoside (eleutheroside B), syringenin 4-*O*-apiosyl- glucoside (polygalatenoside E), alangilignoside C and ligalbumoside A, in accordance with previous works described with *V. album* species ([@b0195], [@b0210], [@b0190], [@b0285]).

Eleutheroside B and polygalatenoside E presented cytotoxic activity against HL-60 and Hell-299 cell lines ([@b0260]). Additionally, [@b0345] demonstrated eleutheroside B cytotoxic activity against MCG-803 cell line with IC50 50.9 µM. Based on the literature data, the presence of phenylpropanoids and lignans in TB and flavanones in TA could be also related to their cytotoxic and apoptotic activities.

Giemsa staining revealed the occurrence of morphological B16F10 changes, induced by TA and TB treatments, mainly characterized by blebs and cell shrinkage, which are suggestive of apoptotic cell death ([@b0330]). In fact, biochemical features of apoptosis were detected after gel electrophoresis analysis, confirming DNA ladder fragmentation into segments of 180--200 multiple base pairs, which is a typical apoptosis pattern ([@b0295]). Additionally, Annexin V-FITC/PI assay confirmed the cell death in a dose-dependent manner since the lower TB concentration (3% v/v) induced a higher percentage of early apoptotic cells. Moreover, using 5% (v/v) of TB and TA, the flow cytometry analyses showed an increase in late apoptosis or other cell death mechanisms.

Finally, the proportion of hypodiploid B16F10 cells in the total cell population was significantly higher after incubation with both tinctures at 5% (v/v), with around 80% of cells in Sub G0 ([@b0005]) ([Fig. 7](#f0035){ref-type="fig"}), confirming the increase of late apoptotic cells detected by Annexin V-FITC/PI-FITC/PI assay ([Fig. 8](#f0040){ref-type="fig"}). The observed increase in apoptotic cells, confirmed by the augmented Sub G0 population was associated with a consistent decrease in G1, without alterations in S or G2/M populations ([Fig. 7](#f0035){ref-type="fig"}, panel B). These evidences suggest that the death-inducing mechanisms promoted by *V. album* tinctures 5% v/v did not impact cell cycle progression. On the other hand, cells treated with TA 3% v/v exhibited enriched populations in S and G2/M phases in association with a decline in G0/G1 after 24 h of incubation. Similar effects using plant extracts on cell cycle progression of cancer cells were previously observed. [@b0120] reported an arrest of breast cancer cell line LA7 in S phase when treated with *Kelussia odoratissima* methanol extracts. Additionally, the population in G1 phase was decreased and the expression of p21 and p27 were augmented ([@b0120]). The arrest in S phase was also observed in Caco-2 and HEPG2 cells treated with *Olea europaea* L*.* ethanol extracts. This effect was accompanied by DNA fragmentation and subsequent cell death induction ([@b0155]).

Previously, [@b0085] showed a G0/G1 arrest in both B16BL6 and B16F10 melanoma cells treated with Korean mistletoe lectin (*V. album* var. *coloratum agglutinin*) and its extract *in vitro*. They also observed an increase in both early and late apoptosis, and that this was probably caused by an increase in the activation of caspases-1, 3, 4, 5, 6, 7, 8, and 9, in a dose-dependently way, accompanied by a significant decrease in the expression of procaspase-3 and 8 ([@b0085]).

Corroborating these and our results, Korean mistletoe lectin (*V. album* var. *coloratum agglutinin*-VCA) increased the survival of mice inoculated with B16-BL6 melanoma cells and inhibited lung metastasis by VCA ([@b0200]).

They also showed that treatment of cells with VCA resulted in growth suppression, nuclear morphological changes, DNA fragmentation, and an increased fraction of cells in sub-G1 consistent with apoptosis, confirming our results. When analyzing anti-angiogenesis of VCA, they observed that vessel growth induced by fat emulsion was decreased. These results suggest that VCA has different mechanisms for inhibiting tumor growth and metastasis by increasing apoptosis and also by inhibiting angiogenesis ([@b0200]).

In the late decade of 1990, [@b0015] had yet observed the effects of *V. album* on the inhibition of lung metastatic colony formation induced by B16F10 melanoma cells in mice, and [@b0150] showed the anticarcinogenic and antimetastatic effects of Iscador on methylcholanthrene-induced sarcoma formation in mice, although the mechanisms in both studies were not identified at that time.

Moreover, [@b0335] showed that low concentrations of *V. album* commercial extracts (Isorel) inhibited B16F10 and HeLa tumor cell lines more strongly than purified lectin-1. For the authors, the therapeutic effect of Isorel is a result of the association of low and high molecular weight components present in the extracts.

Although the above commented researches observed the effects of lectins in the antitumoral effects of *V. album*, in the present work, we evidenced the effects of *V. album* tinctures in a metastatic melanoma murine (B16F10) model for the first time, confirming the wide variety of chemical compounds in the ethanolic *V. album* and their promising antitumoral potential.

5. Conclusion {#s0115}
=============

*V. album* tinctures presented anticancer activity against B16F10 and K562 tumor cell lines. Our results showed a selective tumoral cytotoxicity with apoptosis induction and cell cycle effect. Furthermore, the identified compounds chlorogenic acid, caffeic acid, sakuranetin, naringenin 5-methyl ether, syringenin 4-*O*-glucoside (eleutheroside B), syringenin 4-*O*-apiosyl-glucoside (polygalatenoside E), alangilignoside C and ligalbumoside A are the possible contributors to the antiproliferative and apoptotic effects of *V. album* tinctures, suggesting an interesting potential for the pharmacotherapy of cancer. Based on these results, the present authors suggest further toxicologic investigations with *V. album* tinctures as well as preclinical assays in order to evaluate the clinical potential of these preparations.
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